Compare SMCI & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMCI | BIIB |
|---|---|---|
| Founded | 1993 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1B | 27.1B |
| IPO Year | 2006 | 1996 |
| Metric | SMCI | BIIB |
|---|---|---|
| Price | $31.75 | $190.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 27 |
| Target Price | $39.53 | ★ $194.72 |
| AVG Volume (30 Days) | ★ 19.6M | 886.7K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.86 | ★ 8.79 |
| Revenue | $2,484,929,000.00 | ★ $9,890,600,000.00 |
| Revenue This Year | $90.56 | N/A |
| Revenue Next Year | $19.83 | N/A |
| P/E Ratio | $37.07 | ★ $21.43 |
| Revenue Growth | ★ 11.68 | 2.22 |
| 52 Week Low | $27.61 | $110.04 |
| 52 Week High | $62.36 | $202.41 |
| Indicator | SMCI | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 50.27 | 52.25 |
| Support Level | $28.90 | $170.99 |
| Resistance Level | $33.18 | $202.41 |
| Average True Range (ATR) | 1.56 | 5.34 |
| MACD | -0.01 | -1.04 |
| Stochastic Oscillator | 49.58 | 47.54 |
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data centers, high-performance computing, and the Internet of Things embedded markets. Its solutions include servers, storage systems, modular blade servers, workstations, full-rack scale solutions, networking devices, server sub-systems, and server management. These turn-key solutions are designed, developed, validated, and installed for AI datacenters. The company has one operating segment that develops and provides high-performance server solutions based upon a, modular and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).